{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060243","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.630956+00:00","generated_at":"2026-06-08T13:59:33.735965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lyra reports Q3 net loss $15.7M; Phase 2 CT data shows objective improvement in CRS","bullets":["CT data for LYR-220: ethmoid sinus opacification improved vs sham (p=0.035) at 24 weeks.","SNOT-22 improvement maintained at Week 28: -17.6 points (p=0.007) vs sham.","Cash, equivalents and investments $102.6M, sufficient into Q1 2025.","ENLIGHTEN I Phase 3 fully enrolled; topline results expected 1H 2024.","Net loss $15.7M vs $14.8M year-over-year; R&D spend up to $12.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060243","json":"https://secwatch.observer/filing/0000950170-23-060243.json","markdown":"https://secwatch.observer/filing/0000950170-23-060243.md","text":"https://secwatch.observer/filing/0000950170-23-060243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/0000950170-23-060243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/lyra-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:59:33.735965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db2f1e76020a0e7f5deba0c0752bbad5a7114bf8","claim":"Lyra Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023060243/0000950170-23-060243-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}